Kelly Phillips

Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment.

D Gareth Evans, Kelly-Anne Phillips, Roger L Milne, Robert Fruscio, Cezary Cybulski, Jacek Gronwald, Jan Lubinski, Tomasz Huzarski, Zerin Hyder, Claire Forde, Kelly Metcalfe, Leigha Senter, Jeffrey Weitzel, Nadine Tung, Dana Zakalik, Maria Ekholm, Ping Sun, Steven A Narod, undefined kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group

Journal article  |  2023  |  Br J Cancer

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

C Sessa, J Balmaña, SL Bober, MJ Cardoso, N Colombo, G Curigliano, SM Domchek, DG Evans, D Fischerova, N Harbeck, C Kuhl, B Lemley, E Levy-Lahad, M Lambertini, JA Ledermann, S Loibl, K-A Phillips, S Paluch-Shimon, undefined ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Journal article  |  2023  |  Ann Oncol

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

CE Geyer, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, P Rastogi, K Cui, A Arahmani, G Aktan, AC Armstrong, M Arnedos, J Balmaña, J Bergh, J Bliss, S Delaloge, SM Domchek, A Eisen, F Elsafy, LE Fein, et al.

Journal article  |  2022  |  Ann Oncol

BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase i..

Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.

Amy L Winship, Lauren R Alesi, Sneha Sant, Jessica M Stringer, Aldana Cantavenera, Teharn Hegarty, Carolina Lliberos Requesens, Seng H Liew, Urooza Sarma, Meaghan J Griffiths, Nadeen Zerafa, Stephen B Fox, Emmaline Brown, Franco Caramia, Pirooz Zareie, Nicole L La Gruta, Kelly-Anne Phillips, Andreas Strasser, Sherene Loi, Karla J Hutt

Journal article  |  2022  |  Nature Cancer

Loss of fertility is a major concern for female reproductive-age cancer survivors, since a common side-effect of conventional cyto..

Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?

Kelly-Anne Phillips, Michael L Friedlander

Journal article  |  2022  |  JOURNAL OF CLINICAL ONCOLOGY

Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials

Wanyuan Cui, Kelly-Anne Phillips, Prudence A Francis, Richard A Anderson, Ann H Partridge, Sherene Loi, Sibylle Loibl, Louise Keogh

Journal article  |  2022  |  BREAST

BACKGROUND: Detailed toxicity data are routinely collected in breast cancer (BC) clinical trials. However, ovarian toxicity is inf..

VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

ANJ Tutt, J Garber, RD Gelber, K-A Phillips, A Eisen, OT Johannsson, P Rastogi, KY Cui, S-A Im, R Yerushalmi, AM Brufsky, M Taboada, G Rossi, G Yothers, C Singer, LE Fein, N Loman, D Cameron, C Campbell, CE Geyer

Journal article  |  2022  |  ANNALS OF ONCOLOGY

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.

Charlotte Elizabeth Coles, Benjamin O Anderson, David Cameron, Fatima Cardoso, Richard Horton, Felicia Marie Knaul, Miriam Mutebi, Naomi Lee, undefined Lancet Breast Cancer Commission

Journal article  |  2022  |  Lancet

Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC)

Zhoufeng Ye, Shuai Li, Gillian S Dite, Tuong L Nguyen, Robert J MacInnis, Irene L Andrulis, Saundra S Buys, Mary B Daly, Esther M John, Allison W Kurian, Jeanine M Genkinger, Wendy K Chung, Kelly-Anne Phillips, Heather Thorne, Ingrid M Winship, Roger L Milne, Pierre-Antoine Dugue, Melissa C Southey, Graham G Giles, Mary Beth Terry, et al.

Journal article  |  2022  |  CANCER PREVENTION RESEARCH

UNLABELLED: We considered whether weight is more informative than body mass index (BMI) = weight/height2 when predicting breast ca..

Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?

Wanyuan Cui, Kelly-Anne Phillips, Prudence A Francis, Sherene Loi, Richard A Anderson, Ann H Partridge, Louise A Keogh

Journal article  |  2022  |  Cancer Research

Abstract Background Toxicity data are routinely collected in phase 3 (neo)adjuvant breast cancer (BC) clinical tria..